A Study Evaluating TRIV-573 in Atopic Dermatitis
Eligible age
18–75 yrs
Accepts
All genders
Locations
9 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Sponsor: Triveni Bio
You may qualify if…
- ✓ Has Atopic Dermatitis.
- ✓ Has moderate to severe, active and symptomatic atopic dermatitis.
You may not qualify if…
- ✕ Severe or uncontrolled medical conditions.
- ✕ Use of prohibited medications within stated washout periods.
Where it's recruiting
Fountain Valley · Los Angeles
Boca Raton · Miami
Indianapolis
Bay City
Boardman
Camp Hill
Myrtle Beach
San Antonio
Spokane
Source: ClinicalTrials.gov · NCT07782333 · last updated 2026-10-28